department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

ACADIA PHARMACEUTICALS INC ($ACAD) · pharmadog

PUBLIC COMPANY

$ACADACADIA PHARMACEUTICALS INC

San Diego, CA, USupdated 1h ago

Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, California.

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

5

marketed

2

phase 3

1

catalysts ytd

3

approvals ytd

1

recalls ytd

0

Pipeline(5)

pipeline depth5 products

1Phase 32Marketed2Unknown

pimavanserin tartrate

Phase 3

remlifanserin

Alzheimer's Disease

1 INDICATIONS AND USAGE DAYBUE and DAYBUE STIX are indica…

1 INDICATIONS AND USAGE DAYBUE and DAYBUE STIX are indica…

Upcoming

ACADIA PHARMACEUTICALS INC earnings

ACADIA PHARMACEUTICALS INC

Recent(90d)

earnings (1)

ACADIA PHARMACEUTICALS INC earnings

ACADIA PHARMACEUTICALS INC

view all catalysts →

🐶 Hiring Signal

next earnings Aug 5, 2026

No open roles indexed yet — view ACADIA PHARMACEUTICALS INC jobs →

News

no news has mentioned this company yet

identifiers

ticker

$ACAD

SEC CIK

0001070494

country

US

source

sec_tickers

top tags

Alzheimer's Disease1

mentioned in

0news items

entity-linker matched

$ACAD25.97+3.06%

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

SEC EDGAR · openFDA

last refreshed 11m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Active trials

phase3ACP-204 in Adults With Alzheimer's Disease Psychosisrecruitingn=1,074
phase3ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Studyenrolling by invitationn=752
phase2Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosisrecruitingn=180
phase3Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosisenrolling by invitationn=126
phase2ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Responserecruitingn=153
phase3Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorderterminatedn=209
phase3OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndromeenrolling by invitationn=160
phase3Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndromeactive not recruitingn=170

more trials →

Insider activity

source: SEC Form 4

open-market buys + sells

Apr 7, 26SELLSchneyer Mark C.· EVP, CHIEF FINANCIAL OFFICER2,709 sh @ $22.20−$60K↗
Apr 7, 26SELLKihara James· PRINCIPAL ACCOUNTING OFFICER1,030 sh @ $22.20−$23K↗
Mar 26, 26SELLSchneyer Mark C.· EVP, CHIEF FINANCIAL OFFICER3,171 sh @ $21.65−$69K↗
Mar 26, 26SELLKihara James· PRINCIPAL ACCOUNTING OFFICER1,097 sh @ $21.65−$24K↗
Mar 26, 26SELLSchneyer Mark C.· EVP, CHIEF FINANCIAL OFFICER37 sh @ $21.72−$804↗
Mar 26, 26SELLKihara James· PRINCIPAL ACCOUNTING OFFICER12 sh @ $21.73−$261↗
Mar 25, 26SELLOwen Adams Catherine· Chief Executive Officer11,641 sh @ $21.47−$250K↗
Mar 25, 26SELLSchneyer Mark C.· EVP, CHIEF FINANCIAL OFFICER4,177 sh @ $21.47−$90K↗
Mar 25, 26SELLRhodes Jennifer J· EVP, CHIEF LEGAL OFFICER, SEC3,844 sh @ $21.47−$83K↗
Mar 25, 26SELLThompson Elizabeth H.Z.· EVP, Head of Research & Dev3,435 sh @ $21.47−$74K↗
Mar 25, 26SELLKihara James· PRINCIPAL ACCOUNTING OFFICER833 sh @ $21.47−$18K↗
Feb 9, 26SELLRhodes Jennifer J· EVP, CHIEF LEGAL OFFICER, SEC6,950 sh @ $23.38−$162K↗

routine RSU / option mechanics (6)

Apr 5, 26option exerciseKihara James · PRINCIPAL ACCOUNTING OFFICER2,010 sh
Apr 5, 26option exerciseSchneyer Mark C. · EVP, CHIEF FINANCIAL OFFICER5,276 sh
Apr 5, 26option exerciseKihara James · PRINCIPAL ACCOUNTING OFFICER2,010 sh
Apr 5, 26option exerciseSchneyer Mark C. · EVP, CHIEF FINANCIAL OFFICER5,276 sh
Mar 25, 26option exerciseKihara James · PRINCIPAL ACCOUNTING OFFICER2,142 sh

$ACAD25.97+3.06%

$ACAD25.97+3.06%

Mar 25, 26

option exercise

Schneyer Mark C. · EVP, CHIEF FINANCIAL OFFICER

6,178 sh